Cargando…

Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis

BACKGROUND: Our primary aim was to assess the ability of a non-profit foundation-sponsored clinic network to facilitate access to specialized care for patients with neurofibromatoses (NF), a group of neurogenetic disorders including NF1, NF2, and schwannomatosis (SWN). Our secondary aim was to ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Merker, Vanessa L., Dai, Annie, Radtke, Heather B., Knight, Pamela, Jordan, Justin T., Plotkin, Scott R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114484/
https://www.ncbi.nlm.nih.gov/pubmed/30157837
http://dx.doi.org/10.1186/s12913-018-3471-5
_version_ 1783351200147570688
author Merker, Vanessa L.
Dai, Annie
Radtke, Heather B.
Knight, Pamela
Jordan, Justin T.
Plotkin, Scott R.
author_facet Merker, Vanessa L.
Dai, Annie
Radtke, Heather B.
Knight, Pamela
Jordan, Justin T.
Plotkin, Scott R.
author_sort Merker, Vanessa L.
collection PubMed
description BACKGROUND: Our primary aim was to assess the ability of a non-profit foundation-sponsored clinic network to facilitate access to specialized care for patients with neurofibromatoses (NF), a group of neurogenetic disorders including NF1, NF2, and schwannomatosis (SWN). Our secondary aim was to identify how our findings in NF could be applied more broadly to other rare diseases. METHODS: We retrospectively reviewed aggregate data on patient volume reported by specialty NF clinics in a nonprofit network from 2008 to 2015. We classified clinics as high or low volume for disease type (NF1 and NF2/schwannomatosis) and pediatric/adult care. We compared clinic-level data to self-reported patient-level data from a large online patient registry. RESULTS: Between 2008 and 2015, the number of certified NF clinics grew from 32 to 50, and annual patient volume rose from 6776 to 10,245 patients (13% of the total estimated U.S. NF patient population). For patient registry participants (n = 4476), the median driving distance to the nearest network clinic was 51.3 miles. Driving distances to reach high-volume centers were elevated for adults compared to children (295.8 vs. 67.9 miles), and schwannomatosis and NF2 patients compared to NF1 patients (310.9 vs. 368.1 vs. 161.7 miles). Of registry participants reporting their location of care (n = 2271), only 43.2% received care in a network specialty clinic, with especially low rates of attendance in the Southwest and Far West. CONCLUSIONS: While the number of certified NF clinics and volume of patients seen in these clinics has increased, many NF patients still do not attend specialty clinics and/or travel a significant distance for care. Geographic access to care is more limited for adults, patients with rarer conditions, and patients in the Western U.S. Potential measures to improve access to specialty care for people living with NF and other rare diseases are discussed.
format Online
Article
Text
id pubmed-6114484
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61144842018-09-04 Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis Merker, Vanessa L. Dai, Annie Radtke, Heather B. Knight, Pamela Jordan, Justin T. Plotkin, Scott R. BMC Health Serv Res Research Article BACKGROUND: Our primary aim was to assess the ability of a non-profit foundation-sponsored clinic network to facilitate access to specialized care for patients with neurofibromatoses (NF), a group of neurogenetic disorders including NF1, NF2, and schwannomatosis (SWN). Our secondary aim was to identify how our findings in NF could be applied more broadly to other rare diseases. METHODS: We retrospectively reviewed aggregate data on patient volume reported by specialty NF clinics in a nonprofit network from 2008 to 2015. We classified clinics as high or low volume for disease type (NF1 and NF2/schwannomatosis) and pediatric/adult care. We compared clinic-level data to self-reported patient-level data from a large online patient registry. RESULTS: Between 2008 and 2015, the number of certified NF clinics grew from 32 to 50, and annual patient volume rose from 6776 to 10,245 patients (13% of the total estimated U.S. NF patient population). For patient registry participants (n = 4476), the median driving distance to the nearest network clinic was 51.3 miles. Driving distances to reach high-volume centers were elevated for adults compared to children (295.8 vs. 67.9 miles), and schwannomatosis and NF2 patients compared to NF1 patients (310.9 vs. 368.1 vs. 161.7 miles). Of registry participants reporting their location of care (n = 2271), only 43.2% received care in a network specialty clinic, with especially low rates of attendance in the Southwest and Far West. CONCLUSIONS: While the number of certified NF clinics and volume of patients seen in these clinics has increased, many NF patients still do not attend specialty clinics and/or travel a significant distance for care. Geographic access to care is more limited for adults, patients with rarer conditions, and patients in the Western U.S. Potential measures to improve access to specialty care for people living with NF and other rare diseases are discussed. BioMed Central 2018-08-29 /pmc/articles/PMC6114484/ /pubmed/30157837 http://dx.doi.org/10.1186/s12913-018-3471-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Merker, Vanessa L.
Dai, Annie
Radtke, Heather B.
Knight, Pamela
Jordan, Justin T.
Plotkin, Scott R.
Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_full Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_fullStr Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_full_unstemmed Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_short Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
title_sort increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114484/
https://www.ncbi.nlm.nih.gov/pubmed/30157837
http://dx.doi.org/10.1186/s12913-018-3471-5
work_keys_str_mv AT merkervanessal increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT daiannie increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT radtkeheatherb increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT knightpamela increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT jordanjustint increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis
AT plotkinscottr increasingaccesstospecialtycareforrarediseasesacasestudyusingafoundationsponsoredclinicnetworkforpatientswithneurofibromatosis1neurofibromatosis2andschwannomatosis